Can-Fite sinks 60% to all-time low after PhII/III flop

Bearish interpreters of the interim Phase II/III data Can-Fite ($CANF) presented in 2012 have been proven right. Final top-line results from the trial of CF101 in psoriasis patients showed it failed to meet its primary endpoint, sending shares in the Israeli biotech down 60% to close at a new low for the company. 

The data represent a major blow to Can-Fite and CF101, the oral small molecule A3 adenosine receptor (A3AR) agonist it is developing as a treatment for psoriasis, rheumatoid arthritis and glaucoma. In a trial of 326 patients across the U.S., Europe and Israel, CF101 failed to outperform the placebo. After 12 weeks, 8.5% of the treatment arm showed a 75% or more improvement over the baseline on the Psoriasis Area and Severity Index. Almost 7% of the placebo arm showed the same level of improvement.

Data gathered using the Physicians' Global Assessment score--a secondary endpoint in the trial--were equally underwhelming. Can-Fite CEO Pnina Fishman dangled the possibility of a secondary endpoint and sub-group analysis yielding something positive in front of investors, but the hopes of the biotech and anyone hoping to make a buck out of it have most likely moved on to other drugs and indications. Data from an 88-person Phase II glaucoma trial of CF101 are due later this year. And Can-Fite wrapped up the design-stage of a Phase III rheumatoid arthritis trial of the same drug at the end of 2014.

The psoriasis flop puts a question mark against both programs, which are the most advanced at the company. Beyond the three indications being pursued for CF101, Can-Fite has another A3AR agonist--CF102--in development as a liver cancer treatment. The company dosed the first patient in a Phase II trial of CF102--which is designated an orphan drug by FDA--late last year. Enrollment in the 78-person trial is expected to close in the fourth quarter.

- read the release

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.